Back

Kemp expands protein development control through glycoengineered CHO partnership

Verifying
  • Kemp Proteins partnered with NeuImmune to expand cell line and recombinant protein production capabilities.
  • NeuImmune's platform includes 28 engineered CHO cell lines with varied N-glycan structures.
  • The companies are applying the technology to antibodies targeting Ebola and Sudan virus.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.